Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter, IncellDx Form Cancer Assay Promotion Agreement

NEW YORK — Beckman Coulter Life Sciences and IncellDx said today that they have partnered to promote in Europe four newly developed cancer assays that incorporate technology from each company.

The flow cytometry-based assays were developed by Menlo Park, California-based IncellDx to run on Beckman Coulter instrumentation including its CytoFlex systems. They are designed to perform single-cell analysis for lung and bladder cancers, as well as human papilloma virus-related cancers of the head, neck, and cervix. The kits pair the single-cell functionality of flow cytometry with molecular analysis to get information on mRNA and protein expression as well as cell cycle and/or proliferation, the firms said.

Specific terms of the deal were not disclosed.

"In cancer research it is essential to carry out quantification at the single cell level," IncellDx Founder and CEO Bruce Patterson said in a statement. "Adding our single cell, simultaneous protein, mRNA, and cell cycle/DNA content assays to the exceptional technology behind Beckman Coulter Life Sciences flow cytometry instruments will open up a new era in understanding cancer biology."

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.